SHANGHAI, March 2, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it will release its unaudited financial results for the fourth quarter and full year 2010 ended December 31, 2010 on March 15, 2011. Management will host a conference call to discuss the results at 8:00am New York Time on March 15, 2011 (8:00pm Beijing time on March 15, 2011).

Conference Call

Mr. Michael Hui, founder and Chief Executive Officer, Mr. Kevin Chen, President and Chief Operating Officer, and William Dai, Chief Financial Officer, will discuss the results and take questions following the prepared remarks.

The dial-in details for the live conference call are as follows:



    - U.S. Toll Free Number:  1.800.299.9630
    - International dial-in
     number:                  + 1.617.786.2904
    - China Toll Free Number:                  10 800 152 1490 (North)
                                                10 800 852 1490(South)
    -Hong Kong Toll Free
     Number:                                               800 963 844
    Passcode:                 SHP

A live webcast of the conference call will be available on the investor relations section of the Company's website at: http://www.shangpharma.com.

A telephone replay of the call will be available for seven days from March 15, 2011 to March 22, 2011. The dial-in details for the replay are as follows: 



    - U.S. Toll Free Number: 1-888-286-8010
    - International dial-in
     number:                 +1-617-801-6888
    Passcode:                                85666096

About ShangPharma Corp.

ShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com. 


    For further information, contact:

    ShangPharma Corporation

    Lan Xie, VP of Finance and Operations
    E-mail: IR@shangpharma.com

    Christensen

    In New York
    Kimberly Minarovich,
    Phone: +1 917-533-3268
    E-mail: kminarovich@christensenir.com

    In Hong Kong
    Tip Fleming
    Phone: +852-9212-0684
    Email: tfleming@ChristensenIR.com

SOURCE ShangPharma Corporation